Cardiff Oncology, Inc.

NASDAQ:CRDF

Biotechnology

Healthcare
$0.84 +2.12%

+$0.03 today

Market cap
$65.27M
Beta
1.38
P/E (TTM)
-1.8
EPS (TTM)
-$0.65
52W Low $1.16High $4.56

Volume 0.86M

Average 1.05M

CRDF Purchases of Investments

Cash used to buy marketable securities and other investments.

Cardiff Oncology, Inc.NASDAQ: CRDF

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments declines year over year

Q1 FY2026 purchases of investments of $12.57M (cash outflow) fell 64.0% year over year, behind the -16.8% change in trailing-twelve-month purchases of investments. Sequentially, it rose 110.3% from the prior quarter. Over 3 fiscal years it compounded at -8.0% a year.

Context

  • Purchases of investments amounted to 11992.6% of revenue in FY2025, up 8542.7 pp from a year earlier.
  • Purchases of investments grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -64.0% toward the trailing-twelve-month pace of -16.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$12.57M+110.3% QoQ
Last fiscal yearDec 2025
-$71.12M+201.8% YoY
LTMMar 2026
-$47.87M-16.8% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-64.0%——
1 year+201.8%——
3-year CAGR-8.0%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(71.12M) USD
Year-over-year change
-201.8%

Purchases of Investments vs competitors

How CRDF compares with its peers on the latest reported figures

  • Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -16.8% is the 6th highest of 7, against a peer median of +14.0%.
  • Purchases of investments amounts to 9118.7% of revenue for CRDF, versus a peer median of 1724.6%.
CRDF Competitors
Purchases of Investments for CRDF and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$136.21M USD+21.1%+23.6%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$116.46M USD+88.1%-1.2%6528.2%
PEPGPepGen Inc.LTM Mar 2026$115.7M USD-5.7%——
MOLNMolecular Partners AGLTM Mar 2026CHF 63.3M CHF-67.9%-39.5%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$54.65M USD+7.0%-22.8%1724.6%
CRDFCardiff Oncology, Inc.LTM Mar 2026$47.87M USD-16.8%-8.0%9118.7%
FBRXForte Biosciences, Inc.LTM Mar 2026$0 USD+100.0%——
IPHAInnate Pharma S.A.FY2025€0 EUR——0.0%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding CRDF) —+14.0%-12.0%1724.6%

Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Depreciation & Amortization451K236K398K404K904K
Deferred Income Tax1.32M0000
Stock-Based Compensation3.23M4.26M4.51M4.76M5.69M
Change in Working Capital(1.79M)(380K)6.57M3.17M2.18M
Accounts Receivables(215K)(236K)483K(484K)591K
Inventory00000
Accounts Payables719K1.35M2.83M2.99M2.2M
Other Working Capital(2.29M)(1.49M)3.25M671K(614K)
Other Non-Cash Items2.03M772K(921K)(598K)(848K)
Operating Cash Flow(23.04M)(33.82M)(30.89M)(37.69M)(37.92M)
Capital Expenditures(205K)(892K)(582K)(80K)(44K)
Acquisitions (Net)205K(114K)000
Purchases of Investments(174.39M)(91.23M)(70.08M)(23.56M)(71.12M)
Sales of Investments43.14M130.27M106.86M37.37M73.25M
Other Investing Activities(205K)114K00(744K)
Investing Cash Flow(131.45M)38.15M36.2M13.73M1.34M
Debt Repayment00000
Common Stock Issued34.19M75K053.41M2.58M
Common Stock Repurchased00000
Dividends Paid(24K)(414K)000
Other Financing Activities1.29M414K0373K0
Financing Cash Flow35.45M75K053.78M2.58M
Effect of Forex Changes00000
Net Change in Cash(119.04M)4.4M5.31M29.82M(34M)
Free Cash Flow(23.25M)(34.71M)(31.47M)(37.77M)(37.97M)

Cardiff Oncology, Inc.

NASDAQ:CRDF

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.